Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
← catalyst calendarNCT06376084 · readout in 557 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
532actual
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-23 | actual | When the study began enrolling |
| Primary completion | 2028-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
Primary outcome
what the primary-completion date above is the date OFReal-World Progression Free Survival (rwPFS)
measured Follow up approximately 36 months after last patient in
Publications
- PMID 40978050 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed